1. Introduction
Hepatocellular carcinoma (HCC) is the most prevalent primary malignancy of the liver, accounting for approximately 75% to 85% of all primary liver cancers [1].
A
According to the latest Global Cancer Statistics (2022), HCC remains a leading cause of cancer-related mortality worldwide, ranking third after lung and colorectal cancers [2, 3]. Local ablation is one of the first-line therapeutic modalities for HCC, including percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), and microwave ablation (MWA), which are commonly used in clinical practice[4, 5]. PEI is particularly suitable for small, early-stage tumors due to its technical simplicity, low cost, and favorable safety profile[6, 7]. Its therapeutic effect mainly relies on ethanol-induced cell membrane disruption and protein denaturation, leading to coagulative necrosis and local inflammation[8]. Despite its clinical advantages and the potential to significantly improve overall survival, PEI is often associated with residual tumor and a high rate of recurrence. The lack of effective postoperative management strategies remains a major challenge in current clinical practice.
Relevant studies have demonstrated that the tumor microenvironment (TME) plays a crucial role in cancer progression and therapeutic response [9]. The liver forms a unique immune landscape, characterized by resident Kupffer cells and infiltrating monocyte-derived macrophages, which exhibit considerable heterogeneity and plasticity [10]. Although local ablation therapies effectively eliminate tumor tissue, they are often followed by the development of an immunosuppressive tumor microenvironment (TIME) and the persistence of microscopic residual disease, both of which contribute to tumor recurrence[11, 12]. The extracellular matrix (ECM), a major non-cellular component of the TME, plays a critical role in tumor progression, treatment resistance, and immune evasion. Beyond providing structural support, the ECM regulates cell adhesion, migration, signal transduction, and intercellular interactions, collectively influencing tumor biology[13–15].
In solid tumors such as HCC and pancreatic cancer, excessive deposition of type I collagen within a dense ECM has been recognized as a hallmark of tumor progression and is associated with poor prognosis[16], which can account for more than 60% of tumor volume and is strongly linked to tumor invasion, metastasis, and poor clinical outcomes[17]. The TME is characterized by prominent fibrotic remodeling, including aberrant type I collagen accumulation and infiltration of cancer-associated fibroblasts (CAFs)[18, 19]. This fibrotic barrier disrupts vascular architecture, elevates interstitial fluid pressure (IFP), impairs drug delivery, and restricts immune cell infiltration, ultimately reducing the efficacy of local treatments[20–23]. Moreover, Type I collagen overdeposition contributes to immune evasion by altering matrix architecture and impeding immune accessibility[17, 24, 25].
Type I collagen is mainly distributed in deep ECM regions, where it is densely encapsulated by matrix components and stromal cells, making it largely "concealed" and inaccessible for imaging or therapeutic targeting[26]. Although collagenase delivery has been shown to degrade the ECM and enhance nanoparticle penetration, its clinical translation is limited by poor stability, rapid inactivation, and off-target risks [27, 28]. Therefore, strategies that selectively expose concealed collagen without inducing collateral tissue damage are crucial for overcoming this barrier and enhancing treatment outcomes.
PEI disrupts local tissue structure and is expected to break the barrier-encapsulated state of collagen. Based on this fact, we propose the concept of a "collagen exposure niche" (unmasking effect) to describe the spatial transition of deeply embedded type I collagen from a shielded to an exposed and recognizable state following PEI. PEI disrupts local tissue structure and remodels the ECM, exposing collagen previously sequestered within the tumor stroma to the intercellular and perivascular spaces. This process transforms collagen from an inaccessible barrier into a spatially accessible, recognizable, and targetable molecule.
A
Interestingly, recent studies suggest that local ablation not only induces direct tumor cell death but also promotes the release of tumor-associated antigens (TAAs) and damage-associated molecular patterns (DAMPs), which activate dendritic cells and elicit an "in situ vaccination" effect[29, 30]. Using targeted radioligand therapy (TLR) during this immune activation may improve the clearance of residual tumor cells, reshape the tumor immune environment, and enhance treatment outcomes[11, 30]. Additionally, PEI induces temporary vascular normalization by disrupting abnormal tumor vessels, improving blood flow, and vessel permeability[31, 32]. This creates a therapeutic window to boost drug delivery and immune cell infiltration, helping to overcome ECM-related resistance and improve ablation effectiveness.
A
Compared with conventional radiotherapy targets that often rely on surface molecules or large molecular antigens, the identified collagen exposure structure is highly conserved and widely distributed, and can be efficiently recognized by small-molecule tracers. Based on this, [⁶⁸Ga]/[¹⁷⁷Lu]Lu-DOTA-COL was designed to rapidly access local lesions during the collagen exposure window, enabling both molecular imaging and localized radioligand therapy. This approach overcomes the limitations of restricted targetable regions and delayed radiotherapy timing commonly encountered in the treatment of solid tumors. Moreover, this strategy not only expands the application scope of RLT in combined local treatments but also provides a complete mechanistic chain from structural disruption to target activation and finally to precise intervention for postoperative recurrence management.
2. Result
2.1 Novel tracers were designed and synthesized to specifically target type I collagen
The synthesis of [68Ga]Ga-DOTA-COL is outlined in Fig. 1A. Factors affecting the radiolabeling yield were assessed, including GaCl3 concentration, precursor concentration, and temperature. Optimal conditions involved mixing precursor (45 µg, 20 nmol) with 3 mL GaCl3 at 100°C and pH 4.0 for 15 min. The chemical purity of the precursor was 97.42% ± 0.61%, as determined by analytical HPLC (Fig. 1B), with detailed quality control data provided in Fig. 1C. The radiochemical purity (RCP) of the final radiopharmaceutical exceeded 99%, as assessed by radio-HPLC (Fig. 1D). In vitro stability studies showed that [177Lu]Lu-DOTA-COL incubated in saline maintained a high RCP (Fig. 1E), RCP > 99%, under 5% HSA, slight degradation ( RCR = 91.2%) occurred (Fig. 1E).
2.2 High affinity of the tracers is confirmed in vitro and in vivo
In Hepa1-6 cells (Fig. 2A), [68Ga]Ga-DOTA-COL showed peak uptake at 60 min (1.19 ± 0.06%ID/g), which was competitively inhibited by excess unlabeled precursor (0.35 ± 0.03%ID/g), confirming specific binding to collagen.
Radio-ELISA analysis (Fig. 2B) revealed that [68Ga]Ga-DOTA-COL displayed strong binding affinity towards mouse collagen standard protein, characterized by a Kd value of 66.61 nM (Bmax = 1779). Furthermore, the IC50 value of DOTA-COL was determined to be 8.44 ± 0.02 nM (Fig. 2C), highlighting its high affinity for collagen.
The partition coefficient (Figure S1) of [68Ga]Ga-DOTA-COL was determined as logP = -2.29 ± 0.09, demonstrating its high hydrophilicity with over 98% of radioactivity concentrated in the aqueous phase.
A
In KM mice, the tracer is cleared primarily via renal excretion, demonstrating rapid elimination through the kidneys, with minimal uptake in normal organs such as liver, lung, spleen, and brain
(Figure. S2). 1 h postinjection, the highest uptake was observed in the kidney (80.05 ± 2.93%ID/g), followed by bone (3.20 ± 0.27%ID/g) and Liver (2.57 ± 0.22%ID/g). Tracer uptake decreased rapidly over time in most organs, while remaining relatively stable in bone. Based on biodistribution data, whole-body radiation dose assessments were conducted using OLINDA software. The effective dose for the whole body was calculated to be 3.71E-02 mSv/MBq. The highest doses were observed in the kidneys (1.90 mGy/MBq), followed by the adrenal glands (0.168 mGy/MBq) and spleen (0.168 mGy/MBq). All evaluated radiation doses were relatively low and adhered to safety standards
(Table
2).
Additionally, pharmacokinetic analysis of [68Ga]Ga-DOTA-COL in healthy KM mice demonstrated rapid body clearance. As illustrated in Fig. 2D and described by Eq. 1, [68Ga]Ga-DOTA-COL exhibited a biphasic decay pattern in mice, featuring an exceptionally short biodistribution half-life of 0.46 min, with an elimination phase half-life of 12.08 min.
Ct = 1.83 + 63.95 × e − 0.44t + 74.61 × e − 0.057t (1)
Micro-PET/CT imaging was performed on healthy KM mice. Analysis of the imaging data and region of interest (ROI) analysis revealed elevated uptake values in the kidney and liver at the 1 h time point, with SUVmax values recorded as 8.89 ± 0.33 and 0.61 ± 0.02, respectively. Over time, the signal intensity in the blood pool and liver exhibited a gradual decline. Conversely, tissues such as the brain, muscle, and bone consistently exhibited low signal intensities throughout the imaging period (Fig. 2E and 2F). The findings suggest dynamic metabolic activity in the heart and liver, while metabolism in other tissues remains relatively stable. Furthermore, co-injection of [68Ga]Ga-DOTA-COL with 200 µg of unlabeled DOTA-COL significantly reduced tumor uptake (SUVmax: 0.53 ± 0.03 vs. 0.32 ± 0.01, p = 0.001). In addition, high target-to-nontarget ratios were achieved due to specific accumulation in the tumor and low uptake in non-target organs (Fig. 2G and 2H).
Table 2
Estimates of the mean absorbed radiation dose
|
Target organ
|
Absorbed Dose (mGy/MBq)
|
|
Adrenals
|
1.68E-01
|
|
Brain
|
1.53E-02
|
|
Esophagus
|
5.97E-03
|
|
Eyes
|
3.71E-04
|
|
Gallbladder Wall
|
1.27E-02
|
|
Left colon
|
1.55E-02
|
|
Small Intestine
|
2.65E-02
|
|
Stomach Wall
|
2.37E-02
|
|
Right colon
|
1.02E-02
|
|
Rectum
|
8.26E-02
|
|
Heart Wall
|
2.79E-02
|
|
Kidneys
|
1.90E-00
|
|
Liver
|
3.05E-02
|
|
Lungs
|
1.56E-02
|
|
Pancreas
|
5.39E-03
|
|
Salivary Glands
|
4.55E-04
|
|
Red Marrow
|
5.65E-03
|
|
Osteogenic Cells
|
1.05E-02
|
|
Spleen
|
1.68E-01
|
|
Testes
|
5.41E-04
|
|
Thymus
|
2.92E-02
|
|
Thyroid
|
1.33E-03
|
|
Urinary Bladder Wall
|
2.45E-03
|
|
Total Body
|
1.28E-02
|
|
Effective dose (mSv/MBq)
|
3.17E-02
|
2.3 PEI treatment induces collagen exposure, creating a niche that is therapeutically relevant
The feasibility of monitoring collagen exposure during PEI intervention was evaluated using [68Ga]Ga-DOTA-COL PET. PET scans were performed on days 1, 5, and 10 post-treatment to evaluate the dynamics of Type I collagen (Fig. 3A), revealing significant changes over time that reflected the treatment's influence on the tumor microenvironment. The pre- and post-treatment CT scans of the PEI, sham, and control groups were compared. Notably, the PEI group exhibited clear and pronounced infiltration of anhydrous ethanol (Fig. 3B). As shown in Fig. 3C, the PEI group exhibited substantial uptake at the tumor, with this pronounced accumulation being consistently observable throughout the treatment period (days 1, 5, and 10). The SUVmax values (as shown in Fig. 4A-C) recorded were 0.51 ± 0.26, 0.36 ± 0.009, and 0.34 ± 0.026, respectively. In contrast, the sham and blank groups displayed lower SUVmax values of 0.3 ± 0.02, 0.32 ± 0.05, and 0.27 ± 0.02, and 0.25 ± 0.01, 0.29 ± 0.03, and 0.27 ± 0.08, respectively, with statistically significant differences compared to the PEI group (p < 0.05). However, with time, a gradual decrease in tracer uptake was observed in the PEI group, suggesting that collagen exposure induced by PEI may become less accessible as the ECM remodels.
In Fig. 3D and Fig. 4D, the therapeutic effect was monitored using [18F]F-FDG. On day 1, the uptake value at the tumor site in the PEI group was the lowest (1.21 ± 0.04), while the sham and blank groups exhibited uptake values of 1.69 ± 0.03 and 1.77 ± 0.04, both groups showed significantly higher values than the PEI group (p < 0.05), indicating an initial therapeutic effect of PEI. However, tracer uptake in the PEI group increased over time (1.64 ± 0.08 on day 5 vs. 2.31 ± 0.29 on day 10), which may suggest a gradual loss of efficacy. This trend could potentially serve as an early indicator of tumor recurrence on imaging[33]. Furthermore, on days 5 and 10, the SUVmax values for the Sham and blank groups were 2.50 ± 0.09 and 2.34 ± 0.14, and 2.78 ± 0.14 and 2.90 ± 0.15, respectively, showing relatively stable uptake compared to the PEI group. Additionally, within the [⁶⁸Ga]Ga-DOTA-COL group, the elevated uptake in PEI-treated tumors resulted in a favorable tumor-to-non-target organ ratio (Fig. 3E-F), thereby enhancing tissue contrast.
For the biodistribution of bearing hepa1-6 mice, as shown in Fig.
4G, within 1 h after the injection of [
68Ga]Ga-DOTA-COL, radioactivity was predominantly distributed in the kidneys (67.85 ± 5.06%ID/g, 69.38 ± 4.10%ID/g, 64.31 ± 1.18%ID/g, p > 0.05 ), lungs (3.54 ± 0.64%ID/g, 3.47 ± 0.56%ID/g, 3.38 ± 0.44%ID/g, p > 0.05), and liver (1.67 ± 0.30%ID/g, 1.68 ± 0.12%ID/g, 1.81 ± 0.09%ID/g, p > 0.05), indicating that [
68Ga]Ga-DOTA-COL was primarily excreted via the urinary system. Notably, the highest tracer uptake was observed in tumors of the PEI group (3.66 ± 0.13% ID/g), which could be effectively blocked by co-injection of an excess of unlabeled DOTA-COL (0.53 ± 0.01% ID/g), confirming the specificity of the tracer. In contrast, tumor uptake in the Sham (1.03 ± 0.18% ID/g) and Blank groups (0.54 ± 0.02% ID/g) was significantly lower than that in the PEI group (p < 0.01). As shown in Fig.
4H, following [
18F]F-FDG injection, the PEI group (10.26 ± 0.34%ID/g) exhibited significantly reduced tumor uptake compared to the Sham group (16.70 ± 0.46%ID/g) and Blank group (16.60 ± 0.86%ID/g), which showed relatively higher and comparable uptake levels (p < 0.01). The biodistribution results matched the imaging findings, confirming the tracer's specificity and feasibility.
A
PEI treatment exposes hidden collagen niches in the tumor microenvironment, creating new targets for localized therapy. Collagen revealed by ECM disruption is a practical molecular target, and collagen-targeted tracers enable noninvasive monitoring of ECM changes after ablation.
2.4 Assessment of radiotherapy efficacy immediately after PEI-Induced collagen exposure
Following confirmation of target feasibility, we proceeded to evaluate the combined use of PEI and [177Lu]Lu-DOTA-COL radioligand therapy. Figure 5A illustrates the treatment timeline, while Fig. 5D displays the CT scans before and after PEI treatment, where the Sham group received normal saline instead of anhydrous ethanol. A single dose of 22.2 MBq was administered to each group. On the first day of treatment, SPECT/CT imaging was performed (Fig. 5E), revealing significantly higher radioactive uptake at the tumor site in the PEI group compared to the Sham and Blank groups. Additionally, the PEI combined with 0.6 mCi [177Lu]Lu-DOTA-COL treatment group demonstrated significant inhibition of tumor growth (Fig. 5B-C). Moreover, on day 10 of treatment, [18F]F-FDG PET/CT imaging (Figure S3) demonstrated significantly lower tracer uptake in the tumor region of the PEI group (SUVmax, 0.57 ± 0.04) compared to the Sham (SUVmax, 1.81 ± 0.02) and Blank (SUVmax, 1.87 ± 0.04) groups, further supporting the sustained efficacy of the therapeutic intervention. In Fig. 5F, the biodistribution data, which are consistent with the imaging results, show that tumor uptake in the PEI group(6.48 ± 0.043%ID) was significantly higher than in the Sham (1.42 ± 0.18%ID) and Blank (1.83 ± 0.14%ID) groups (p < 0.0001). The tumor-to-background ratio (TBR) was markedly increased in the PEI group, reaching (4.37 ± 0.74%ID), compared to (1.62 ± 1.07%ID) and (1.54 ± 1.11%ID) in the Sham and Blank group, respectively, indicating enhanced tracer delivery efficiency to the tumor site. Co-injection with unlabeled DOTA-COL (1.12 ± 0.36%ID) effectively blocked tracer accumulation in the tumor, further confirming the specificity of the tracer. These findings demonstrate effective delivery to the collagen exposure target induced by PEI and underscore the potential therapeutic relevance of this approach.
Throughout the study, all treatment groups maintained stable body weight and showed no observable signs of distress, as shown in Figure S4 (A-H). Comprehensive hematological and biochemical analyses, including liver and kidney function tests, revealed no abnormalities, confirming the absence of systemic toxicity. These findings demonstrate that the treatment was well tolerated and safe.
2.5 Investigating the interplay between ECM Remodeling, collagen deposition, and tumor recurrence
Given the marked therapeutic effect achieved by targeting collagen after PEI, we further investigated the relationship among collagen exposure, ECM remodeling, and tumor recurrence. This analysis not only helps to evaluate the potential of exposed collagen as a molecular imaging target but also provides critical insights into the dynamic changes of the extracellular matrix within the tumor microenvironment. On day 1 after PEI treatment, immunohistochemical staining for Ki67 and α-SMA (Fig. 6A-B) showed markedly reduced expression in the PEI group compared to the sham and control groups. Quantitative analysis (Fig. 6C-D) confirmed that Ki67 (PEI: Sham: blank = 5.02 ± 1.65: 13. 19 ± 1.80: 13. 47 ± 2.02) and α-SMA (PEI: Sham: blank = 9.41 ± 1.36: 19.41 ± 1.73: 19.32 ± 1.83) levels were significantly decreased, indicating suppression of early tumor cell proliferation and stromal activation. By days 5 and 10, Ki67 (PEI: Sham: Blank = 9.53 ± 1.09: 14. 69 ± 2.78: 14.63 ± 1.57 VS PEI: Sham: Blank = 17.78 ± 1.76: 19.85 ± 3.09: 19.27 ± 3.77) expression gradually increased, while α-SMA (PEI: Sham: Blank = 9.53 ± 1.09: 14. 69 ± 2.78: 14.63 ± 1.57 VS PEI: Sham: blank = 17.05 ± 1.71: 20.92 ± 1.94: 21.09 ± 1.78) levels showed a slight rise, suggesting tumor tissue regeneration and ECM remodeling following treatment.
H&E staining (Fig. 6E) further supported these findings, showing disorganized tissue architecture and enlarged necrotic regions in the PEI group across all time points. Grayscale analysis of cell density (Fig. 6F) showed an initial drop on day 1 (4.90 ± 1.43), followed by a gradual recovery on day 5 (8.4 ± 0.9) and 10 (13.35 ± 2.83), indicating progressive tissue reconstruction. Interestingly, we analyzed the correlation between tumor uptake of the [68Ga]Ga-DOTA-COL tracer and the positive areas of Ki67, α-SMA, and H&E at days 1, 5, and 10 after PEI (Figure S5 A-C). The results showed a significant negative correlation on day 1, with correlation coefficients (r = -0.8801, p = 0.0039;r = -0.9570, p = 0.0002; r = -0.8661, p = 0.0054) for these three markers. With the progression of treatment time, the correlation remained statistically significant (p < 0.05), indicating that this tracer holds promise as an early predictor of ECM remodeling.
Immunofluorescence staining on day 10 (Fig. 6G) revealed a substantial accumulation of CD163⁺ and CD11b⁺ cells at the margins of the necrotic area, suggesting the infiltration of immunosuppressive myeloid populations and the formation of a tumor-supportive microenvironment.
H&E staining (Fig. 6H) revealed that on the first day after PEI treatment, tumor tissue structure was markedly disrupted, tissue density in the ablation zone decreased, and collagen-rich channels were evident. By day 10, the tumor matrix had become denser, tissue density increased, and the collagen channels were nearly closed. Concurrently, Ki67 immunostaining indicated low tumor cell proliferation on day 1, whereas by day 10, Ki67 expression was markedly elevated, reflecting the regrowth of residual tumor cells.
Based on these observations, we proposed a mechanistic model illustrating the microenvironmental changes following PEI (Fig. 6I). PEI induces local necrosis and disruption of the ECM structure, releasing damage-associated signals that trigger a transient immune activation. However, this is followed by the recruitment of M2-Type macrophages, leading to a shift toward an immunosuppressive microenvironment, which may facilitate immune evasion by residual tumor cells and contribute to recurrence.
2.6 Collagen-Targeted radiotherapy reduces M2 macrophage infiltration and suppresses tumor growth.
To further investigate whether local radiotherapy targeting exposed collagen could interrupt ECM remodeling and the associated recurrence process, histopathological analysis of tumor tissues was performed on day 10 following the combined PEI and radiotherapy treatment. Immunohistochemistry and H&E staining results demonstrated that in the PEI + [177Lu]Lu-DOTA-COL group, CD163 (Fig. 7B) expression significantly decreased over time and was markedly lower than in the Sham + [177Lu]Lu-DOTA-COL group and the Blank + [177Lu]Lu-DOTA-COL group. Concurrently, infiltration of CD4⁺ and CD8⁺ T cells was substantially increased, indicating enhanced local immune activation (Fig. 7C and 7D). Compared to the sham + [177Lu]Lu-DOTA-COL and Blank + [177Lu]Lu-DOTA-COL groups, Ki67 expression in the ablation zone of the combined treatment group was significantly reduced, suggesting effective inhibition of tumor cell proliferation. α-SMA expression declined, while type I collagen levels showed a continuous upward trend, reflecting progressive repair and remodeling of the fibrotic matrix (Fig. 7F). Although dense fibrotic tumor stroma has been reported to impede drug penetration and compromise treatment efficacy[33,34], other studies have found that higher levels of type I collagen and related fibrosis markers correlate positively with improved patient survival[35,36]. Notably, tumor volume in the PEI + [177Lu]Lu-DOTA-COL group was significantly smaller than in control groups (p < 0.001). H&E staining (Fig. 7E) further revealed a sustained decrease in tissue density in this group, supporting the potential clinical benefit of immediate targeted therapy following PEI to suppress tumor recurrence.
As shown in Fig. 7A, this treatment strategy exploits the disruption of dense ECM in the tumor microenvironment induced by PEI to open a pathway into the tumor, exposing deposited collagen and enabling precise delivery of therapeutic radionuclides. Through this approach, the accumulation and retention of the radioligand therapy [177Lu]Lu-DOTA-COL within the tumor microenvironment are enhanced, effectively reversing immunosuppression. Additionally, targeted delivery promotes a stronger antitumor immune response, evidenced by increased infiltration of CD4⁺ and CD8⁺ T cells and significant inhibition of tumor cell proliferation (reduced Ki67 expression). Furthermore, the treatment slows fibrotic matrix remodeling, shown by a gradual decrease in α-SMA levels and a mild increase in type I collagen. Together, these mechanisms contribute to improved local tumor control after PEI and reduced risk of tumor recurrence.
3. Discussion
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. For decades, surgical resection and transarterial chemoembolization (TACE) have been the local treatment for HCC. With the advancement of image-guided percutaneous ablation techniques, therapeutic strategies for HCC have undergone significant evolution [34]. Among these, percutaneous ethanol injection (PEI) is widely used due to its low cost, technical simplicity, and clinical accessibility, and has been included in current treatment guidelines[35]. However, PEI remains associated with a high recurrence rate, with the literature reporting local recurrence rates as high as 80% within five years [36]. Accurate evaluation of PEI efficacy and effective postoperative management remain critical clinical challenges. In this study, we developed a dual-modality molecular tracer, [⁶⁸Ga]Ga/[¹⁷⁷Lu]Lu-DOTA-COL, that targets Type Ⅰ collagen. PEI disrupted the dense ECM, exposing collagen within the tumor and enabling targeted delivery of therapeutic radioligand. This strategy not only improved treatment precision but also helped clarify the local mechanisms contributing to tumor recurrence following ablation.
Regarding tracer preparation, [⁶⁸Ga]Ga-DOTA-COL was synthesized via manual radiolabeling, with a labeling yield of 79.3% ± 0.8%, radiochemical purity exceeding 95% after purification, and a molar activity of 19.01 ± 0.67 GBq/µmol, meeting quality control standards for radiopharmaceuticals. In vitro studies showed that the tracer exhibited time-dependent uptake in Hepa1-6 cells, which was significantly inhibited by co-incubation with unlabeled precursor (IC₅₀ = 8.44 nmol/L). ELISA assays demonstrated strong binding affinity to type I collagen (Kd = 66.61 nM). In vivo pharmacokinetic analysis revealed moderate initial uptake in non-target tissues (blood, heart, lungs, muscle) followed by rapid clearance, consistent with the short half-life of the tracer (12.08 min). The kidneys were identified as the main site of non-target accumulation, but the rapid clearance profile indicates good biosafety and imaging suitability. Additionally, the estimated whole-body effective dose (3.17 × 10−² mSv/MBq) of [⁶⁸Ga]Ga-DOTA-COL complied with established safety standards for radiopharmaceuticals. These results demonstrate that the tracer possesses high targeting specificity for its intended target, both in vitro and in vivo.
Previous studies have utilized [⁶⁸Ga]Ga-CBP8 PET/MRI to assess fibrosis in solid tumors after chemotherapy or radiotherapy, demonstrating promising translational potential in pancreatic cancer[37, 38]. However, these approaches have primarily focused on treatment-induced fibrotic responses and lacked investigation into the relationship between collagen quantification and ECM remodeling following chemical ablation procedures such as PEI.
Histopathological analysis revealed that PEI caused pronounced structural alterations within the tumor, including decreased cell density and increased necrotic regions as early as day 1 post-treatment. Quantitative analysis revealed the lowest tumor cell density on day 1, followed by gradual increase on days 5 and 10, indicating potential tumor regrowth. Immunohistochemistry further demonstrated reduced Ki67 and α-SMA expression in the PEI group on day 1, suggesting early inhibition of tumor cell proliferation and stromal activity. However, both markers increased over time, reflecting progressive stromal remodeling and partial recovery of the tumor-supportive microenvironment, which may facilitate recurrence. Notably, [⁶⁸Ga]Ga-DOTA-COL PET/CT imaging sensitively reflected these pathological changes, confirming its value for real-time, noninvasive assessment of ECM alterations after PEI.
Building on the concept of collagen exposure in the tumor microenvironment following PEI, we conducted combined local radiotherapy using [177Lu]Lu-DOTA-COL. Since type I collagen is primarily located in the deep tumor stroma, conventional antibody-based large molecules face challenges in effectively penetrating the tumor interior. In contrast, the peptide-based tracer used here has a smaller molecular weight and particle size, resulting in higher specific activity and improved vascular permeability, enabling more efficient delivery and distribution. On day 1 post-PEI, SPECT/CT imaging revealed significantly increased probe uptake in the tumor, with a spatial distribution closely matching previous [68Ga]Ga-DOTA-COL PET imaging. This confirms the tracer-specific recognition of PEI-induced exposed collagen. Biodistribution analysis further demonstrated preferential accumulation in type I collagen-rich regions, supporting its potential as a targeted radiotherapeutic agent. Significantly, this radiotherapy effectively inhibited tumor growth, demonstrating the therapeutic value of this precise delivery strategy. This approach overcomes the ECM barrier and improves both the precision and efficiency of therapeutic agent delivery within the tumor microenvironment, offering a promising strategy for targeted radiotherapy.
The mechanism of tumor recurrence after PEI ablation was then examined. Immunofluorescence showed that the expression of the M2 macrophage marker CD163⁺ and the myeloid cell marker CD11b was significantly increased in the PEI-only group. Previous studies have shown that M2 macrophages are recruited during tissue repair, promoting collagen deposition, fibrotic remodeling, and an immunosuppressive environment that supports tumor survival and recurrence[39]. In contrast, treatment combining PEI with [¹⁷⁷Lu]Lu-DOTA-COL significantly reduced the recruitment of CD163-positive M2 macrophages and eased the immunosuppressive state caused by PEI.
Additionally, the combined treatment increased infiltration of CD4⁺ and CD8⁺ T cells in the tumor, suggesting that low-dose radiotherapy applied during the PEI-induced "immune window" may promote immunogenic cell death and enhanced the antitumor immune response [40]. Ki67 staining showed that this combination effectively suppressed tumor cell proliferation, while H&E staining revealed clear tissue necrosis and lower tumor density.
Notably, type I collagen in the PEI + [¹⁷⁷Lu]Lu-DOTA-COL combination group was more concentrated at the tumor edges, forming "island-like" clusters that may provide a matrix niche supporting residual tumor cells[41]. This suggests that even with radiotherapy and immune activation, small residual tumors may persist within collagen-rich areas. Longitudinal monitoring of tumor volume further demonstrated that the combined treatment significantly delayed tumor recurrence, with superior efficacy compared to PEI alone.
Overall, this study reveals the therapeutic mechanism from three key angles. First, tumor recurrence following PEI is associated with increased infiltration of M2-like macrophages. Second, PEI + [¹⁷⁷Lu]Lu-DOTA-COL reduces macrophage accumulation while enhancing the infiltration of CD4⁺ and CD8⁺ T cells, thereby boosting antitumor immunity. Third, PEI disrupts the extracellular matrix, exposing previously shielded collagen and enabling precise delivery of targeted radiotherapy. Together, these findings highlight the potential of this approach for improving post-ablation outcomes.
Despite these promising results, certain limitations should be noted. [⁶⁸Ga]Ga-DOTA-COL exhibited relatively high nonspecific liver uptake, which may affect imaging contrast. Although the tumor-to-liver ratio remained acceptable (Tumor / Heart = 1.89 ± 0.25, Tumor / Liver = 1.37 ± 0.13, p = 0.06), further structural optimization of the tracer is warranted to enhance specificity and clinical applicability. In addition, this study was conducted in a preclinical stage; future clinical studies are necessary to validate the safety, imaging performance, and therapeutic efficacy of this approach in patients.
5. Materials and Methods
5.1 Chemicals and reagents
68-Ga was obtained from a 68Ge/68Ga radionuclide generator (ITG, Germany), and 177-Lu was supplied by Isotope Technologies Munich SE (Germany). Both radionuclides were used to label the DOTA-COL ligand. The precursor DOTA-COL was synthesized by WuXi AppTec (Wuhan) Co., Ltd. (China). Trifluoroacetic acid (TFA), acetonitrile, and ethanol were sourced from Shanghai Aladdin Biochemical Technology Co., Ltd. (China) and Honeywell International Inc. (USA), respectively. Sep-Pak C18-Light cartridges were obtained from Waters (USA), and the HPLC was equipped with an Agilent 1200 series instrument (USA). Imaging was performed using a small animal PET/CT imaging system (Super Nova, Pingsheng, Shanghai, China). The reagents used for cell culture were purchased from Gibco (Thermo Fisher Scientific, China) and included culture medium, fetal bovine serum (FBS), phosphate buffer (PBS), and trypsin.
5.2 Cell culture and animal models
Hepa1-6 cells (RRID: CVCL_0327, ATCC® CRL-1830 ™), originally derived from the BW7756 tumor in a C57BL/6 mouse, were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Hepa1-6 cells were cultivated in DMEM medium, and media were supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin solution (PS) at 37℃ in 5% carbon dioxide, and the cells were routinely tested and confirmed to be free of mycoplasma contamination.
Male C57BL/6J mice were purchased from Beijing Vital River Laboratory Animal Technology (Beijing, China). Hepa1-6 cells (0.1 mL, 1 × 10
7 cells/ mL) were separately injected into the right axilla of male C57BL/6J mice. Tumors on the right flanks of the mice were allowed to grow to approximately 0.5–0.8 cm in diameter, and then the animals were subjected to imaging and in vivo biodistribution experiments. All animal experiments were performed at the Beijing Institute for Cancer Prevention and Treatment.
A
A
The studies were approved by the Institutional Animal Care and Use Committee (IACUC) under protocol number: EAEC 2024-03, and conducted under the authority of animal use license number: SYXK (Beijing) 2021-0031.
5.3 Radiolabeling and Quality Control
The radiolabeling method of [68Ga]Ga-DOTA-COL is as follows: [⁶⁸Ga]GaCl₃ (4 mL, 0.05M HCl) was obtained from ⁶⁸Ge/⁶⁸Ga nuclide generator (ITG Co., Ltd., Germany). 3 mL of [⁶⁸Ga]GaCl₃ (250–300 MBq) was added to 180 µL of 1 M sodium acetate solution to adjust the pH to 4.0, DOTA-COL (20 nmol, 22 µg) was then added and incubated at 100°C for 15 min.177-Lu labeling is performed in an HCl-NaAc buffering system, pH adjusted to about 5.0, again at 100°C for 15 min. After the radiolabeling reaction is completed, an identical purification and quality control process is applied to both labeling reactions. After the reaction solution was diluted with 8 mL of deionized water, the Sep-Pak C18-Light column (activated with 5 mL of ethanol and 10 mL of water in the pre-treatment) was eluted with 0.5 mL of 50% ethanol and then diluted with 5 mL of 0.9% sodium chloride solution. The product was sterile filtered through a 0.2 µm polytetrafluoroethylene (PTFE) filter membrane. The radiochemical yield and radiochemical purity (RCP) of the end product were determined using radioactive high-performance liquid chromatography (1200 series, Agilent, USA).
5.4 Stability and Partition Coefficient
The in vitro stability of [68Ga]Ga-DOTA-COL and [177Lu]Lu-DOTA-COL was analyzed by incubating the radiopharmaceutical in saline or in 5% human serum albumin (HAS) for 4 h, respectively. The radiochemical purity was determined by radio-HPLC.
For the octanol-water partition assay, 10 µL of the purified [68Ga]Ga-DOTA-COL was added to a 1.5 mL tube (n = 5) containing 490 µL of 0.1 M PBS (pH 7.4) and 500 µL of octanol. The mixture was vortexed for 3 min and further centrifuged (3000 × rpm) for 5 min. Then, a small portion (50 µL) was taken out from each phase and counted with a γ counter (Wizard II, Perkin Elmer Inc., Germany). The partition coefficient was calculated as the count in the octanol divided by the count in the phosphate-buffered saline, and the value was expressed as logP (mean ± SD).
5.5 Cell uptake
For the cell uptake experiment, Hepa1-6 cells were seeded on 24-well plates ( 2 × 105 cells per well) with 500 µL of complete medium overnight before the experiment. The cells were washed with cold PBS (pH 7.4, 0.01 M) twice and then incubated with 74 kBq of [68Ga]Ga-DOTA-COL in 500 µL of fresh medium without FBS for 10, 30, 60, and 120 min at 37°C. For the blocking experiment, cells were coincubated with non-radiolabeled cold precursor, DOTA-COL (1µg/well). After 10, 30, 60, and 120 min, the medium was removed and the cells were washed twice with cold PBS (pH 7.4, 0.01 M) and then lysed with 200 µL of 0.1 M NaOH. The lysate was collected and counted with a γ counter. The results were normalized to 1 × 10⁶ cells and expressed as a percentage of the dose administered (%AD/10⁶ cells). The experiment was repeated three times at each time point.
5.6 Binding affinity assay
For the binding affinity assay, the dissociation constant (Kd) values of [68Ga]Ga-DOTA-COL to collagen were tested as follows. Radio-enzyme-linked immunosorbent assay (Radio-ELISA) was used to assess the affinity between [68Ga]Ga-DOTA-COL and Collagen standard protein (14695-1AP, Proteintech, China). The Collagen protein was dissolved in the antigen coating solution and plated in a 96-well polystyrene Stripwell™ microplate with 200 µL (0.1 µg) per well, then stored at 4 ℃ overnight. After washing five times with PBST (Phosphate-buffered Saline Tween-20), each well was blocked with 200 µL of 5% no-fat milk and incubated at 37°C for 2 h. The radiopharmaceutical agent [68Ga]Ga-DOTA-COL was diluted in saline to prepare 12 concentrations (14.8, 7.2, 3.7, 1.85, 0.74, 0.37, 0.185, 0.074, 0.037, 0.0185, 0.0074, and 0.0037 MBq/mL). Subsequently, 100 µL of each concentration was added to the respective well and incubated at 37°C for 2 h, with four replicates per concentration. After removing the tracer, the wells were washed five times with PBST to remove any unbound material. Finally, the remaining samples in the wells were collected and quantified using a γ-counter. The Kd was calculated using the one-site total binding model in GraphPad Prism 9.5.1 software. The experiment was repeated three times.
5.7 Competitive binding assay
For the competitive binding assay, a range of concentrations of unlabeled precursor (from 0.1 nM to 10 µM) was added to cells containing a constant activity of radiolabeled [68Ga]Ga-DOTA-COL (74 kBq/well). After a 30 min incubation at 37°C, the cells were washed twice with cold PBS (pH 7.4, 0.01 M) and lysed with 200 µL of 0.1 M NaOH. The resulting lysates were collected and quantified using a γ counter. Each concentration experiment was performed in triplicate. The IC50 value of DOTA-COL was determined through nonlinear curve fitting in GraphPad Prism 9.5.1 software (GraphPad Software, San Diego, CA, USA).
5.8 Small animal biodistribution study
For the animal biodistribution study, male KM mice (4 weeks old, 18–20 g) were divided into 4 groups (n = 4). They were intravenously injected with [68Ga]Ga-DOTA-COL (200 µL, 1.11 MBq / mouse), with a 1% injected dose of [68Ga]Ga-DOTA-COL used as a control. Mice were sacrificed at 5 min, 30 min, 1 h and 2 h postinjection under anesthesia. Organs of interest were collected, weighed, and counted using a γ counter. Additionally, 10 samples of the 1% injected dose were counted as standards. The biodistribution of [68Ga]Ga-DOTA-COL in the organs of KM mice is expressed as %ID/g (mean ± SD). Meanwhile, Hepa1-6 tumor-bearing mice were randomly assigned to four groups (n = 4 per group). The PEI and Sham groups received their respective treatments one day prior to tracer injection. Each mouse was administered [68Ga]Ga-DOTA-COL via tail vein injection (200 µL, 1.11 MBq). In the blocking group, an additional 200 µg of unlabeled DOTA-COL was co-injected to assess binding specificity.1 h postinjection, the mice were euthanized by cervical dislocation. Organs of interest, including blood, heart, liver, spleen, lungs, kidneys, small intestine, large intestine, muscle, bone, brain, and tumor, were collected, weighed, and radioactivity measured. 10 samples containing 1% of the injected dose were used as standards. The final uptake in each organ was expressed as the percentage of the injected dose per gram of tissue (% ID/g).
In addition, to further evaluate the efficacy of the treatment and the in vivo distribution of the tracer after treatment, biodistribution experiments of [177Lu]Lu-DOTA-COL and [18F]F-FDG were carried out on the first day following PEI treatment. Mice were administered the tracers via tail vein injection and euthanized 1 h after injection. The administered doses were 3.7 MBq per mouse for [¹⁷⁷Lu]Lu-DOTA-COL and 1.11 MBq per mouse for [¹⁸F]F-FDG. Then, the interested organs were collected, weighed, and radioactivity was measured using a γ counter. The results were expressed as the percentage of injected dose per gram of tissue (%ID/g, mean ± SD).
5.9 Pharmacokinetics study
For the pharmacokinetic study, male KM mice (n = 5). In brief, each mouse received an intravenous injection of 3.7 MBq of [68Ga]Ga-DOTA-COL. Small blood samples were obtained via the orbital vein at 1 min, 3 min, 5 min, 10 min, 15 min, 30 min, 45 min, 60 min, 90 min, 120 min, 180 min, and 240 min postinjection. The blood samples were weighed and subsequently counted using a γ counter. The results were expressed as percentage injected dose per gram (%ID/g, mean ± SD).
5.10 PEI treatment
In this part, a partial ablation Hepa1-6 tumor-bearing mouse model was established using PEI. When tumor volumes reached approximately 150 mm³, mice were randomly assigned to three groups: PEI treatment (n = 8), sham treatment (n = 8), and blank control (n = 8). During PEI treatment, an insulin needle was inserted along the longest diameter of the tumor, at a depth of 1/2 to 2/3 of the tumor diameter, administering 25 µL of ethanol every 30s for 10 min, followed by slow withdrawal of the needle. The sham group underwent the same procedure, except that saline was injected instead of ethanol. During injection, mice were anesthetized through inhalation of 2% isoflurane. CT scans were used to assess ethanol leakage post-ablation. The day of PEI treatment initiation was defined as day 0. The therapeutic efficacy of PEI was visualized using [68Ga]Ga-DOTA-COL and [18F]F-FDG with PET imaging conducted at multiple time points after treatment. Tumor volume and mouse body weight were monitored every 2 to 3 days, with tumor volume calculated as (length × width2)/2. Euthanasia was carried out if the tumor volume reached 1000 mm³ or if tumor ulceration occurred.
5.11 PET/CT and SPECT/CT Imaging of Hepa1-6 Xenograft Mice under Various Treatments
[68Ga]Ga-DOTA-COL and [18F]F-FDG PET/CT scans were performed on day 1, 5, and 10 post-treatment in the PEI group, the sham group, and the blank control group. Different groups of Hepa1-6 tumor-bearing mice were injected with 7.4 MBq of [68Ga]Ga-DOTA-COL or [18F]F-FDG via the tail vein (n = 5). Imaging was performed 1 h after injection, following an overnight fast for the 18F-FDG PET/CT scans. For the blocking study, mice were co-injected with [68Ga]Ga-DOTA-COL and 200 µg of unlabeled precursor DOTA-COL on day 1 after PEI treatment. After anesthesia with 2.5% (v/v) isoflurane, micro-PET/CT imaging was performed for 15 min at 1 h postinjection. Micro-PET/CT (Super Nova PET/CT, Pingseng Health Care, China) was utilized, beginning with a CT scan followed by a 10 min static PET scan under 2% isoflurane anesthesia. Subsequently, PET images were reconstructed using Avatar 3 software (Pingseng Healthcare). Quantitative image analysis was conducted by defining regions of interest (ROIs) and calculating the standard uptake value (SUV).
5.12 Radioligand therapy studies (RLT) and SPECT/CT imaging
Hepa1-6 tumor-bearing mice were randomly divided into three groups: the PEI group (PEI treatment initiated at a tumor volume of 150 mm³, n = 15), the Sham group (received normal saline following the same procedure as the PEI group, n = 15), and the Blank group (n = 15). A single dose of [¹⁷⁷Lu]Lu-DOTA-COL (22.2 MBq) was administered on day 1 post-PEI. SPECT/CT imaging (MOLECUBES, Belgium) was performed on days 1, and H&E and IHC analyses were conducted on days 1, 5, and 10 to evaluate therapeutic efficacy. Tumor volume and body weight were monitored every two days. Euthanasia was carried out if the tumor volume reached 1000 mm³ or if tumor ulceration occurred.
5.13 Radiation dosimetry
The radiation dosimetry of [68Ga]Ga-DOTA-COL tracers for PET imaging in adult male patients was assessed based on biodistribution studies conducted in KM mice. Source organs, including the heart, liver, spleen, lung, kidney, stomach wall, small intestine, large intestine, muscle, bone, brain, and residual body, were chosen for analysis. Areas under the curve (AUCs) were computed by fitting the activity concentration-time curve using mono-exponential models. Radiation dosimetry calculations were performed using OLINDA/EXM software (version 1.0, Hermes Medical Solutions AB).
5.14 H&E staining, immunohistochemical analysis
For the H&E staining and immunohistochemical analysis, upon sacrifice of the tumor-bearing mice, the tumor tissues were fixed in 4% formaldehyde. Paraffin-embedded sections were dewaxed using an alcohol gradient for immunohistochemistry (IHC). The primary antibody was incubated overnight at 4°C, followed by a 30 min incubation with different secondary antibodies: Ki67 (CST, 9129, 1:200), α-SMA (abcam, ab124964, 1:2000), CD4 (abcam, ab183685, 1:500), CD8 (abcam, ab209775, 1:500), CD163 (Sevier Biotech Inc, GB113109, 1:200), Collagen Ⅰ (Sevier Biotech Inc, GB11022, 1:1000) at room temperature, as per manufacturer instructions for dilutions. Sections were then subjected to DAB staining, nuclear counterstaining, dehydration, sealing, and microscopic examination. Additionally, pathological sections were dewaxed, followed by hematoxylin and eosin staining, dehydration, and mounting.
5.15 Fluorescence immunostaining
For the fluorescence immunostaining, Paraffin sections were sequentially dewaxed using an eco-friendly dewaxing agent and graded ethanol solutions, followed by thorough rinsing with distilled water. Antigen retrieval was then performed in a high-pressure cooker using EDTA buffer (pH 9.0), and sections were allowed to cool naturally to room temperature. After washing with TBST buffer, the tissue area was outlined with a hydrophobic barrier pen (Fuzhou Maixin Biotechnology Development Co., Ltd., PEN-0002). The sections were blocked with 10% donkey serum (AntGene, #ANT051) at 37°C for 30 min. After removing the blocking solution, primary antibodies diluted in TBST were applied, and the sections were incubated overnight at 4°C. The next day, sections were brought to room temperature for 15 min, washed with TBST, and then incubated with Alexa Fluor® 488-conjugated donkey anti-rabbit IgG secondary antibodies (CD56, CST, 99746, 1:50; CD4, Abcam, ab183685, 1:500; CD8, Abcam, ab209775,1:500; CD11B, Abcam, ab133357, 1:1000; CD163, Sevier Biotech Inc, GB113109, 1:200; PDL1, CST,64988S,1:100; IFNγ, affinity, DF6045, 1:200), at 37°C for 45 min. After thorough washing, nuclei were counterstained with DAPI (Solarbio, C0060) for 5 min. Finally, the sections were mounted with fluorescence mounting medium, stored at 4°C in the dark, and imaged using a fluorescence microscope (Olympus Corporation, BX53).
Statistical analysis:
Statistical analyses were performed using GraphPad Prism 9.5.1 (San Diego, USA), including two-way ANOVA, one-way ANOVA, t-test, and Pearson correlation coefficient (r) analysis. Statistical significance was set at p < 0.05, and data are presented as mean ± standard deviation (SD) throughout the manuscript.